CORD: comparsion of recommended doses of ACE inhibitors and angiotensin II receptor blockers

Vnitrni Lekarstvi

Volumn 55, Issue 5, 2009, Pages 481-488

  Spinar J ^a   Vitovec J ^b   Soucek M ^b   Dusel L ^c   Pavlik T ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Cough; Hypertension; Isolated systolic hypertension; Losartan; Metabolic parameters; Ramipril

Indexed keywords

LOSARTAN; RAMIPRIL; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RECOMMENDED DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; RAMIPRIL;

EID: 67649128737     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension 2007; 25: 1105-1187.
2. Dahlof B, Devereux RB, Kjeldsen SE et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
3. Sever PS, Dahlöf B, Poulter NF et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
4. PoulterNR,WedelH,DahlöfBetal.ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rate noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913.
5. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angioten-sin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
7. The SOLVD investigators. Effect of ena-lapril on survival in patients with reduced left ventricular ejection fractions and heart failure. N EnglJ Med 1991; 325: 293-302.
8. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement study. The SAVE investigators. N EnglJ Med 1992; 327: 669-677.
9. Flather MD, Yusuf S, Køber L et al. Long term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-lnhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.
10. Pfeffer MA, Domanski M, Rosenberg Y et al. Prevention of events with an-giotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. Am J Cardiol 1998; 82: 25H-30H.
11. Pitt B. ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in peace? N EnglJ Med 2004; 351: 2115-2117.
12. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N EnglJ Med 2000; 342: 145-153.
13. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997; 349: 747-752.
14. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
15. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
16. Dickstein K, Kjekshus J. OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752-760.
17. Pfeffer MA, McMurrayJJV, Velazquez EJ et al. VALIANT Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N EnglJ Med 2003; 349: 1893-1906.
18. Vidt DC Telmisartan, ramipril, or both in patients at high risk for vascular events. N EnglJ Med 2008; 358: 1547-1559.
19. SpinarJ, VitovecJ, Spinarova Let al. A comparison of intervention with losartan or captopril in acute myocardial infarction. EurJ Heart Fail 2000; 2: 91-100.
20. SpinarJ, VitovecJ, Pluhacek L et al. First dose hypotension after angiotensin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction. IntJ Car-diol 2000; 75: 197-204.
21. Fox KM. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003; 362: 782-788.
22. Pepine CJ, Handberg EM, Cooper-De-Hoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
23. NissenSE,Tuzcu EM, Libby Petal. CA-MELOT investigators. Effect of antihyper-tensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
24. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597.
25. Dahlof B, Anderson DR, Arora V et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tole-rability independent of age orgenderin patients with hypertension. J Clin Hypertens 2007; 9 (Suppl A): A157-A376.
26. Mancia G, Seravalle G, Grassi G. Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens Suppl 2002; 20:S21-S27.
27. Benetos A, Zureik M, Morcet J et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000; 35: 673-680.
28. Waeber B, Mourad JJ. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. AmJ Hypertens 2006; 19: 985-986.
29. BlacherJ, Staessen JA, Girerd X et al. Pulse pressure not mean pressure determines cardiovascular risk in elderly hypertensive patients. Arch Intern Med 2000; 160: 1085-1089.
30. Staessen JA, Gasowski J, Wang JG et al. Risk of untreated and treated isolated systolic hypertension in the elderly: me-ta-analysis of outcome trials. Lancet 2000; 355: 865-872.
31. Turnbull F, Neal B, Pfeffer M etal. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
32. Veronesi M, Cicero AF, Prandin MG et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vase Health Risk Manag 2007; 3: 999-1005.